Search

Your search keyword '"Li, Pui"' showing total 520 results
Start Over Author "Li, Pui"
520 results on '"Li, Pui"'

2. Real-World Sensitization and Tolerance Pattern to Seafood in Fish-Allergic Individuals

Author

Leung, Agnes S.Y., Wai, Christine Y.Y., Leung, Nicki Y.H., Ngai, Noelle Anne, Chua, Gilbert T., Ho, Po Ki, Lam, Ivan C.S., Cheng, James W.C.H., Chan, Oi Man, Li, Pui Fung, Au, Ann W.S., Leung, Chloris H.W., Cheng, Nam Sze, Tang, Man Fung, Fong, Brian L.Y., Rosa Duque, Jaime S., Wong, Joshua S.C., Luk, David C.K., Ho, Marco H.K., Kwan, Mike Y.W., Yau, Yat Sun, Lee, Qun Ui, Chan, Wai Hung, Wong, Gary W.K., and Leung, Ting Fan

Published
2024
Full Text
View/download PDF

3. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling

Author

Liu, Chengfei, Armstrong, Cameron M, Ning, Shu, Yang, Joy C, Lou, Wei, Lombard, Alan P, Zhao, Jinge, Wu, Chun-Yi, Yu, Aiming, Evans, Christopher P, Tepper, Clifford G, Li, Pui-kai, and Gao, Allen C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prostate Cancer, Urologic Diseases, Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Aetiology, 2.1 Biological and endogenous factors, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Targeting androgen signaling with the second-generation anti-androgen drugs, such as enzalutamide (Enza), abiraterone (Abi), apalutamide (Apal), and darolutamide (Daro), is the mainstay for the treatment of castration-resistant prostate cancer (CRPC). While these treatments are effective initially, resistance occurs frequently. Continued expression of androgen receptor (AR) and its variants such as AR-V7 despite AR-targeted therapy contributes to treatment resistance and cancer progression in advanced CRPC patients. This highlights the need for new strategies blocking continued AR signaling. Here, we identify a novel AR/AR-V7 degrader (ARVib) and found that ARVib effectively degrades AR/AR-V7 protein and attenuates AR/AR-V7 downstream target gene expression in prostate cancer cells. Mechanistically, ARVib degrades AR/AR-V7 protein through the ubiquitin-proteasome pathway mediated by HSP70/STUB1 machinery modulation. ARVib suppresses HSP70 expression and promotes STUB1 nuclear translocation, where STUB1 binds to AR/AR-V7 and promotes its ubiquitination and degradation. ARVib significantly inhibits resistant prostate tumor growth and improves enzalutamide treatment in vitro and in vivo. These data suggest that ARVib has potential for development as an AR/AR-V7 degrader to treat resistant CRPC.

Published
2021

4. Cell-Based Functional IgE Assays Are Superior to Conventional Allergy Tests for Shrimp Allergy Diagnosis

Author

Wai, Christine YY, Leung, Nicki YH, Leung, Agnes SY, Shum, Yuki, Leung, Patrick SC, Chu, Ka Hou, Kwan, Yat Wah, Lee, Qun Ui, Wong, Joshua SC, Lam, Ivan CS, Li, Pui Fung, Xu, Kary JY, Lam, Cheuk Yin, Sun, Jinlyu, Wong, Gary WK, and Leung, Ting Fan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Foodborne Illness, Food Allergies, Clinical Research, Inflammatory and immune system, Allergens, Animals, Food Hypersensitivity, Humans, Immunoglobulin E, Skin Tests, Tropomyosin, Shrimp allergy, Basophil activation test, IgE crosslinking-induced luciferase expression test, DBPCFC, CD63, CCR3, IgE crosslinking–induced luciferase expression test, Immunology
Abstract

BackgroundThe diagnosis of shellfish allergy currently relies on patient history, skin prick test (SPT), and serum specific IgE (sIgE) quantification. These methods lack sufficient diagnostic accuracy, whereas the gold standard of oral food challenges is risky and burdensome. Markers of reactivity and severity of allergic reactions to shellfish will improve clinical care of these patients.ObjectivesThis study compared the diagnostic performance of SPT, sIgE, basophil activation test (BAT), and IgE crosslinking-induced luciferase expression (EXiLE) test for shrimp allergy.MethodsThirty-five subjects with documented history of shrimp allergic reactions were recruited and grouped according to results of double-blind, placebo-controlled food challenge (DBPCFC). In addition to routine diagnostics, BAT (Flow CAST) and EXiLE test with shrimp extract and tropomyosin were performed.ResultsOf 35 subjects, 15 were shrimp allergic with pruritus, urticaria, and itchy mouth on DBPCFC, whereas 20 were tolerant to shrimp. Tropomyosin only accounted for 53.3% of sensitization among subjects with challenge-proven shrimp allergy. BAT using shrimp extract as stimulant showed the highest area under curve value (0.88), Youden Index (0.81), likelihood ratio (14.73), odds ratio (104), and variable importance (4.27) when compared with other assays and tropomyosin diagnosis. Results of BAT significantly correlated with those of EXiLE (r = 0.664, P < .0001).ConclusionsBAT is a more accurate diagnostic marker for shrimp allergy than SPT and shrimp sIgE, whereas the EXiLE test based on an IgE crosslinking assay is a good alternative to BAT. Tropomyosin may not be the most important shrimp allergen in Chinese, which warrants further investigation to search for other major allergens and diagnostic markers.

Published
2021

5. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.

Author

Armstrong, Cameron M, Liu, Chengfei, Liu, Liangren, Yang, Joy C, Lou, Wei, Zhao, Ruining, Ning, Shu, Lombard, Alan P, Zhao, Jinge, D'Abronzo, Leandro S, Evans, Christopher P, Li, Pui-Kai, and Gao, Allen C

Subjects
Cell Line, Tumor, Humans, Prostatic Neoplasms, Benzamides, Nitriles, Phenylthiohydantoin, Androstenes, Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate, Androgen Antagonists, Steryl-Sulfatase, Androgens, Neoplasm Staging, Cell Proliferation, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Male, Prostatic Neoplasms, Castration-Resistant, Carcinogenesis, RNA-Seq, Aging, Genetics, Clinical Research, Urologic Diseases, Cancer, Prostate Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeMost patients with prostate cancer receiving enzalutamide or abiraterone develop resistance. Clinical evidence indicates that serum levels of dehydroepiandrosterone sulfate (DHEAS) and biologically active DHEA remain in the high range despite antiandrogen treatment. The conversion of DHEAS into DHEA by steroid sulfatase (STS) may contribute to sustained intracrine androgen synthesis. Here, we determine the contribution of STS to treatment resistance and explore the potential of targeting STS to overcome resistance in prostate cancer.Experimental designSTS expression was examined in patients and cell lines. In vitro, STS activity and expression were modulated using STS-specific siRNA or novel STS inhibitors (STSi). Cell growth, colony formation, androgen production, and gene expression were examined. RNA-sequencing analysis was conducted on VCaP cells treated with STSi. Mice were treated with STSis with or without enzalutamide to determine their effects in vivo.ResultsSTS is overexpressed in patients with castration-resistant prostate cancer (CRPC) and resistant cells. STS overexpression increases intracrine androgen synthesis, cell proliferation, and confers resistance to enzalutamide and abiraterone. Inhibition of STS using siRNA suppresses prostate cancer cell growth. Targeting STS activity using STSi inhibits STS activity, suppresses androgen receptor transcriptional activity, and reduces the growth of resistant C4-2B and VCaP prostate cancer cells. STSis significantly suppress resistant VCaP tumor growth, decrease serum PSA levels, and enhance enzalutamide treatment in vitro and in vivo.ConclusionsThese studies suggest that STS drives intracrine androgen synthesis and prostate cancer proliferation. Targeting STS represents a therapeutic strategy to treat CRPC and improve second-generation antiandrogen therapy.

Published
2020

7. Outcomes of double-blind, placebo-controlled food challenges with seawater and freshwater shrimps in Chinese patients with adverse food reactions to shrimp

Author

Leung, Ting Fan, primary, Yan Wai, Christine Yee, additional, Li, Pui Fung, additional, Wan Leung, Chloris Hei, additional, Tavares, Tiffany Nicole, additional, Cheng, Nam Sze, additional, Yuen Fong, Brian Leong, additional, Yeung, Miu Nam, additional, Chan, Oi Man, additional, Shan Au, Ann Wing, additional, Ngai, Noelle Anne, additional, Yin Leung, Agnes Sze, additional, and Chu, Ka Hou, additional

Published
2024
Full Text
View/download PDF

8. Clinical outcome of dorsal versus lateral plating in proximal phalangeal fracture: A retrospective study.

Author

Tam, Cheuk Yin, Koo, Jeffrey Justin Siu Cheong, Li, Pui Man Carmen, Leung, Kam Yiu Adrian, Chau, Wai Wang, and Ho, Pak Cheong

Subjects
FINGER joint, T-test (Statistics), DATA analysis, FRACTURE fixation, ORTHOPEDIC implants, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, CHI-squared test, BONE fractures, FINGER injuries, MEDICAL records, ACQUISITION of data, STATISTICS, COMPARATIVE studies, DATA analysis software, RANGE of motion of joints, GRIP strength, EVALUATION
Abstract

Background: Plating of proximal phalangeal fracture is the commonly adopted fixation method. However, whether placing the implant at the dorsal or lateral aspect of the phalanx can yield a better clinical outcome is still under debate. Our study aims to compare the functional outcome of dorsal plating versus lateral plating in patients suffering from a proximal phalangeal fracture. Methods: A retrospective comparative study was performed comparing the clinical outcome of dorsal and lateral plating in proximal phalangeal fracture. Fourteen patients from our center with a total of 17 proximal phalangeal fractures (excluding the thumb) were included in this study. The total range of movement and range of movement of each finger joint together with grip strength were the main focuses of this study. Operative complications and the need for subsequent related operations were also analyzed. Results: Nine cases were treated by dorsal plating and eight cases adopted lateral plating. There was no significant difference in demographic data between the two groups with a mean follow-up period of 20.75 months. Lateral plating provided better total range of movement (dorsal plating (D): 203.9 ± 35.2 vs. lateral plating (L): 248.8 ± 23.7; p -value = 0.01) and percentage change in total range of movement (D: 79.41% ± 10.35, L: 94.47% ± 6.09; p -value < 0.01). There was less extension lag in lateral plating as evidenced by the sum of extension lag of the three finger joints being statistically significantly smaller (D: 32.8 ± 14.2 vs. L: 4.44 ± 6.2, p < 0.01). Less percentage decrease in grip strength compared with the contralateral normal hand was also noted in the lateral plating group (D: 68.17% ± 31.11 vs. L: 98.13% ± 10.88, p = 0.02). Conclusions: Based on this study, lateral plating provides better functional outcomes in terms of range of movement, extension lag, and grip strength than dorsal plating. Level of Evidence: Therapeutic, retrospective comparative study, Level III. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Exploration of Textile–Silicone Composites and Materials for Personal Impact-Resistant Protection.

Author

Chan, Mei-Ki, Li, Pui-Ling, Yick, Kit-Lun, Yip, Joanne, and Ng, Sun-Pui

Subjects
*COMPOSITE materials, *THERMOPHYSICAL properties, *SILICONE rubber, *COMPOSITE structures, *PERSONAL protective equipment, *THERMAL comfort
Abstract

Conventional cushioning materials such as silicone sheets which have been recommended for resisting impact generally cause discomfort to the wearer from heat and perspiration. With the increasing need for personal protective equipment, textile–silicone composite structures are proposed in this study to reduce acute impact and moisture while enhancing thermal comfort. The influence of the composite structure and thickness on the mechanical and thermal properties of textile–silicone materials are systematically investigated. The results show that an additional knitted powernet fabric as a composite material can significantly improve the tensile properties of silicone rubber by up to 315%. However, only a slight improvement is found in the thermal conductivity (up to 16%), compression elasticity (up to 18%) and force reduction performance (up to 3.6%). As compared to inlaid spacer fabric, which has also been used for cushioning and preserving thermal comfort, the textile–silicone composites have higher tensile and compression elasticity, exhibit force reduction with the largest difference of 43% and are more thermally conductive, with increases more than 38%. The findings of this study introduced a cost-effective new silicone–textile composite for optimal impact protection and wear comfort for protective applications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, Thomas, Sufi M, Kim, Seungwon, Yeh, Joanne I, Ferris, Robert L, Johnson, Jonas T, Duvvuri, Umamaheswar, Lee, Jessica, Sahu, Nivedita, Joyce, Sonali, Freilino, Maria L, Shi, Haibin, Li, Changyou, Ly, Danith, Rapireddy, Srinivas, Etter, Jonathan P, Li, Pui-Kai, Wang, Lin, Chiosea, Simion, Seethala, Raja R, Gooding, William E, Chen, Xiaomin, Kaminski, Naftali, Pandit, Kusum, Johnson, Daniel E, and Grandis, Jennifer R

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Biological Sciences, Rare Diseases, Cancer, Dental/Oral and Craniofacial Disease, Biotechnology, Genetics, Animals, Cell Line, Tumor, Female, Gene Expression, Head and Neck Neoplasms, Humans, Injections, Intralesional, Male, Mice, Mice, Nude, Middle Aged, Oligonucleotides, Antisense, Random Allocation, STAT3 Transcription Factor, Xenograft Model Antitumor Assays, Oncology and Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

UnlabelledDespite evidence implicating transcription factors, including STAT3, in oncogenesis, these proteins have been regarded as "undruggable." We developed a decoy targeting STAT3 and conducted a phase 0 trial. Expression levels of STAT3 target genes were decreased in head and neck cancers following injection with the STAT3 decoy compared with tumors receiving saline control. Decoys have not been amenable to systemic administration due to instability. To overcome this barrier, we linked the oligonucleotide strands using hexaethylene glycol spacers. This cyclic STAT3 decoy bound with high affinity to STAT3 protein, reduced cellular viability, and suppressed STAT3 target gene expression in cancer cells. Intravenous injection of the cyclic STAT3 decoy inhibited xenograft growth and downregulated STAT3 target genes in the tumors. These results provide the first demonstration of a successful strategy to inhibit tumor STAT3 signaling via systemic administration of a selective STAT3 inhibitor, thereby paving the way for broad clinical development.SignificanceThis is the fi rst study of a STAT3-selective inhibitor in humans and the fi rst evidence that a transcription factor decoy can be modifi ed to enable systemic delivery. These findings have therapeutic implications beyond STAT3 to other “undruggable” targets in human cancers.

Published
2012

18. Data from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 2 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 3 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 2 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 1 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 1 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 4 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 5 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 7 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure Legends 1-7, Table Legends 1-2 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 6 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Author

Sen, Malabika, primary, Thomas, Sufi M., primary, Kim, Seungwon, primary, Yeh, Joanne I., primary, Ferris, Robert L., primary, Johnson, Jonas T., primary, Duvvuri, Umamaheswar, primary, Lee, Jessica, primary, Sahu, Nivedita, primary, Joyce, Sonali, primary, Freilino, Maria L., primary, Shi, Haibin, primary, Li, Changyou, primary, Ly, Danith, primary, Rapireddy, Srinivas, primary, Etter, Jonathan P., primary, Li, Pui-Kai, primary, Wang, Lin, primary, Chiosea, Simion, primary, Seethala, Raja R., primary, Gooding, William E., primary, Chen, Xiaomin, primary, Kaminski, Naftali, primary, Pandit, Kusum, primary, Johnson, Daniel E., primary, and Grandis, Jennifer R., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure S1 from Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer

Author

Armstrong, Cameron M., primary, Liu, Chengfei, primary, Liu, Liangren, primary, Yang, Joy C., primary, Lou, Wei, primary, Zhao, Ruining, primary, Ning, Shu, primary, Lombard, Alan P., primary, Zhao, Jinge, primary, D'Abronzo, Leandro S., primary, Evans, Christopher P., primary, Li, Pui-Kai, primary, and Gao, Allen C., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figures 1-4 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Author

Lin, Li, primary, Hutzen, Brian, primary, Zuo, Mingxin, primary, Ball, Sarah, primary, Deangelis, Stephanie, primary, Foust, Elizabeth, primary, Pandit, Bulbul, primary, Ihnat, Michael A., primary, Shenoy, Satyendra S., primary, Kulp, Samuel, primary, Li, Pui-Kai, primary, Li, Chenglong, primary, Fuchs, James, primary, and Lin, Jiayuh, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 1 from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells

Author

Kroon, Paula, primary, Berry, Paul A., primary, Stower, Michael J., primary, Rodrigues, Greta, primary, Mann, Vincent M., primary, Simms, Matthew, primary, Bhasin, Deepak, primary, Chettiar, Somsundaram, primary, Li, Chenglong, primary, Li, Pui-Kai, primary, Maitland, Norman J., primary, and Collins, Anne T., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells

Author

Kroon, Paula, primary, Berry, Paul A., primary, Stower, Michael J., primary, Rodrigues, Greta, primary, Mann, Vincent M., primary, Simms, Matthew, primary, Bhasin, Deepak, primary, Chettiar, Somsundaram, primary, Li, Chenglong, primary, Li, Pui-Kai, primary, Maitland, Norman J., primary, and Collins, Anne T., primary

Published
2023
Full Text
View/download PDF

38. Data from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Author

Lin, Li, primary, Hutzen, Brian, primary, Zuo, Mingxin, primary, Ball, Sarah, primary, Deangelis, Stephanie, primary, Foust, Elizabeth, primary, Pandit, Bulbul, primary, Ihnat, Michael A., primary, Shenoy, Satyendra S., primary, Kulp, Samuel, primary, Li, Pui-Kai, primary, Li, Chenglong, primary, Fuchs, James, primary, and Lin, Jiayuh, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure and Table Legends from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Author

Lin, Li, primary, Hutzen, Brian, primary, Zuo, Mingxin, primary, Ball, Sarah, primary, Deangelis, Stephanie, primary, Foust, Elizabeth, primary, Pandit, Bulbul, primary, Ihnat, Michael A., primary, Shenoy, Satyendra S., primary, Kulp, Samuel, primary, Li, Pui-Kai, primary, Li, Chenglong, primary, Fuchs, James, primary, and Lin, Jiayuh, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 1 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Author

Lin, Li, primary, Hutzen, Brian, primary, Zuo, Mingxin, primary, Ball, Sarah, primary, Deangelis, Stephanie, primary, Foust, Elizabeth, primary, Pandit, Bulbul, primary, Ihnat, Michael A., primary, Shenoy, Satyendra S., primary, Kulp, Samuel, primary, Li, Pui-Kai, primary, Li, Chenglong, primary, Fuchs, James, primary, and Lin, Jiayuh, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 2 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Author

Lin, Li, primary, Hutzen, Brian, primary, Zuo, Mingxin, primary, Ball, Sarah, primary, Deangelis, Stephanie, primary, Foust, Elizabeth, primary, Pandit, Bulbul, primary, Ihnat, Michael A., primary, Shenoy, Satyendra S., primary, Kulp, Samuel, primary, Li, Pui-Kai, primary, Li, Chenglong, primary, Fuchs, James, primary, and Lin, Jiayuh, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 2 from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells

Author

Kroon, Paula, primary, Berry, Paul A., primary, Stower, Michael J., primary, Rodrigues, Greta, primary, Mann, Vincent M., primary, Simms, Matthew, primary, Bhasin, Deepak, primary, Chettiar, Somsundaram, primary, Li, Chenglong, primary, Li, Pui-Kai, primary, Maitland, Norman J., primary, and Collins, Anne T., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 5 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Author

Lin, Li, primary, Hutzen, Brian, primary, Zuo, Mingxin, primary, Ball, Sarah, primary, Deangelis, Stephanie, primary, Foust, Elizabeth, primary, Pandit, Bulbul, primary, Ihnat, Michael A., primary, Shenoy, Satyendra S., primary, Kulp, Samuel, primary, Li, Pui-Kai, primary, Li, Chenglong, primary, Fuchs, James, primary, and Lin, Jiayuh, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results